Every material Form 8-K bioAffinity Technologies, Inc. has filed with the SEC since October 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
bioAffinity Technologies reported third-quarter 2026 revenue of approximately $1.1 million, down from approximately $1.4 million a year earlier, which it attributed to lower reimbursement per CyPath Lung test and a slight decline in cases at its Precision Pathology Laboratory Services subsidiary. The net loss widened to approximately $5.3 million from $5.1 million, as the operating loss grew to approximately $3.5 million from $2.3 million, and cash fell to approximately $2.6 million at September 30, 2026, which matters to shareholders given the company's continuing losses.
Q3 2026 revenue was approximately $1.1 million versus approximately $1.4 million in Q3 2025; nine-month CyPath Lung testing revenue rose 79% to approximately $1.1 million.
Q3 net loss was approximately $5.3 million versus $5.1 million; loss from operations was approximately $3.5 million versus $2.3 million.
Cash and cash equivalents were approximately $2.6 million at September 30, 2026, down from $6.4 million at December 31, 2025; a financing after quarter-end generated approximately $4.0 million in gross proceeds.
bioAffinity Technologies announced in a press release that it will take part in the Lung Cancer Initiative of North Carolina's Battle of the Blues on November 5, 2026, to highlight its CyPath Lung test during National Lung Cancer Awareness Month. The filing contains no financial results, guidance, or transaction details, so it offers shareholders no new financial information.
Event: Lung Cancer Initiative of North Carolina's Battle of the Blues, November 5, 2026
Company product featured: CyPath Lung, a noninvasive lung cancer detection test marketed as a Laboratory Developed Test
The 8-K contains no financial figures, guidance, or transaction terms
bioAffinity Technologies said it will sponsor a Learning Theater presentation at CHEST 2026, the annual meeting of the American College of Chest Physicians, on the use of its CyPath Lung test in lung cancer risk assessment and pulmonary nodule management. The filing includes no financial results, guidance, or financing terms, so the announcement is an event update rather than a change in the company's financial position.
Presentation is scheduled for October 21, 2026, from 12:30 to 1:15 p.m. MST in Learning Theater 4 at the Phoenix Convention Center, Phoenix, Arizona.
Chief Medical Officer Gordon H. Downie, MD, PhD, is listed as the presenter.
The presentation will discuss preliminary research on a new asthma and COPD test, which the filing describes as investigational and not available for clinical use.
The company's Medical and Scientific Advisory Board will also meet in conjunction with CHEST 2026.
bioAffinity Technologies announced it will present new research on investigational sputum-based tests that measure lung inflammation and protein biomarkers, including targets of asthma and COPD biologic drugs, at the CHEST 2026 meeting. The tests are not validated, not cleared or approved by the FDA, and not available for clinical or diagnostic use, so the update is a research milestone rather than a financial or commercial event.
Poster titled "Sputum as a Diagnostic Tool for the Measurement of Lung Inflammation in Asthma" is scheduled for October 20, 2026, 1:45-2:30 p.m. at the Phoenix Convention Center.
Chief Medical Officer Gordon Downie will lead a discussion at CHEST 2026 on October 21 at 12:30 p.m. in Learning Theater 4.
The tests are investigational, not validated, not FDA cleared or approved, and not currently available for clinical or diagnostic use.
The filing states no financial results, revenue or guidance figures.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every bioAffinity Technologies, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →